Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NUDT1 | P36639 | 1/20 | 0.66 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.57 |
| ▸ | MPO | P05164 | 2/20 | 0.48 |
| ▸ | MGMT | P16455 | 4/20 | 0.48 |
| ▸ | CDK1 | P06493 | 2/20 | 0.48 |
| ▸ | CCNB1 | P14635 | 2/20 | 0.48 |
| ▸ | CCNA2 | P20248 | 2/20 | 0.48 |
| ▸ | CDK2 | P24941 | 2/20 | 0.48 |
| ▸ | CCNA1 | P78396 | 2/20 | 0.48 |
| ▸ | DCPS | Q96C86 | 1/20 | 0.47 |
| ▸ | RAB9A | P51151 | 2/20 | 0.46 |
| ▸ | NPC1 | O15118 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.46 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.46 |
| ▸ | TPO | P07202 | 1/20 | 0.46 |
| ▸ | EPX | P11678 | 1/20 | 0.46 |
| ▸ | LMNA | P02545 | 1/20 | 0.46 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.46 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8509853 | 0.83 | MGMT (0.50) | NUDT1HRH4MPOMGMTDCPS | |
| SCHEMBL11464975 | 0.83 | NUDT1 (0.67) | NUDT1HRH4MGMTCDK1CCNB1 | |
| SCHEMBL8508427 | 0.83 | DHFR (0.52) | NUDT1HRH4MPOLMNAMAOB | |
| SCHEMBL9341580 | 0.83 | NUDT1 (0.62) | NUDT1HRH4MPOMGMTCDK1 | |
| SCHEMBL3930094 | 0.83 | NUDT1 (0.62) | NUDT1HRH4MPOMGMTCDK1 | |
| SCHEMBL26660073 | 0.83 | NUDT1 (0.67) | NUDT1HRH4MPOMGMTCDK1 | |
| SCHEMBL26660074 | 0.83 | NUDT1 (0.67) | NUDT1HRH4MPOMGMTCDK1 | |
| SCHEMBL10398841 | 0.83 | ALOX5 (0.49) | NUDT1HRH4MPOCDK1CCNB1 | |
| SCHEMBL13884791 | 0.83 | NUDT1 (0.57) | NUDT1HRH4MPORAB9ANPC1 | |
| SCHEMBL1899392 | 0.80 | NUDT1 (0.51) | NUDT1HRH4MPORAB9ANPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 65 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3873484-B1 | NOVEL STING AGONISTS | VENENUM BIODESIGN LLC (US) | 2023-08-23 | — | — | EP | disclosed |
| EP-3873484-B1 | NOVEL STING AGONISTS | VENENUM BIODESIGN LLC (US) | 2023-08-23 | — | — | EP | disclosed |
| US-20220048936-A1 | NOVEL STING AGONISTS | Venenum Biodesign, LLC (US) | 2022-02-17 | — | — | US | disclosed |
| US-11161864-B2 | Sting agonists | Venenum Biodesign, LLC (US) | 2021-11-02 | — | — | US | disclosed |
| US-11161864-B2 | Sting agonists | Venenum Biodesign, LLC (US) | 2021-11-02 | — | — | US | disclosed |
| EP-3873484-A1 | NOVEL STING AGONISTS | Venenum Biodesign, LLC (US) | 2021-09-08 | — | — | EP | disclosed |
| US-20200131209-A1 | NOVEL STING AGONISTS | Venenum Biodesign, LLC | 2020-04-30 | — | — | US | disclosed |
| US-20200131209-A1 | NOVEL STING AGONISTS | Venenum Biodesign, LLC | 2020-04-30 | — | — | US | disclosed |
| US-9656969-B2 | Polymer film, retardation film, polarizing plate, liquid crystal display, and compound | FUJIFILM CORPORATION (JP) | 2017-05-23 | — | — | US | disclosed |
| US-9656969-B2 | Polymer film, retardation film, polarizing plate, liquid crystal display, and compound | FUJIFILM CORPORATION (JP) | 2017-05-23 | — | — | US | disclosed |
| WO-1997020843-A1 | PYRIMIDINE DERIVATIVES AND GUANINE DERIVATIVES, AND THEIR USE IN TREATING TUMOUR CELLS | CANCER RESEARCH CAMPAIGN TECHNOLOGY LIMITED (GB) | 1997-06-12 | — | — | WO | disclosed |
| EP-0775142-A1 | SUBSTITUTED O6 -BENZYLGUANINES AND 6(4)-BENZYLOXYPYRIMIDINES | THE UNITED STATES OF AMERICA, as represented by THE SECRETARY, Department of Health and Human Services (US) | 1997-05-28 | — | — | EP | disclosed |
| EP-0775142-A1 | SUBSTITUTED O6 -BENZYLGUANINES AND 6(4)-BENZYLOXYPYRIMIDINES | THE UNITED STATES OF AMERICA, as represented by THE SECRETARY, Department of Health and Human Services (US) | 1997-05-28 | — | — | EP | disclosed |
| US-5612468-A | GENETIC ENGINEERING | THE UNITED STATES OF AMERICA AS REPRESENTED BY THE DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 1997-03-18 | — | — | US | disclosed |
| EP-0759927-A1 | PTERIDINE NUCLEOTIDE ANALOGS AS FLUORESCENT DNA PROBES | THE GOVERNMENT OF THE UNITED STATES OF AMERICA as represented by the SECRETARY OF THE DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 1997-03-05 | — | — | EP | disclosed |
| US-5525606-A | CHEMOTHERAPEUTIC ANTITUMOR AGENT | THE UNITED STATES OF AMERICA AS REPRESENTED BY THE DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 1996-06-11 | — | — | US | disclosed |
| US-5525711-A | MONOMERS FOR DNA AMPLIFICATION PROCEDURES | THE UNITED STATES OF AMERICA AS REPRESENTED BY THE SECRETARY OF THE DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 1996-06-11 | — | — | US | disclosed |
| WO-1996004281-A1 | SUBSTITUTED O6-BENZYLGUANINES AND 6(4)-BENZYLOXYPYRIMIDINES | THE UNITED STATES OF AMERICA, REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 1996-02-15 | — | — | WO | disclosed |
| WO-1996004281-A1 | SUBSTITUTED O6-BENZYLGUANINES AND 6(4)-BENZYLOXYPYRIMIDINES | THE UNITED STATES OF AMERICA, REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 1996-02-15 | — | — | WO | disclosed |
| WO-1995031469-A1 | PTERIDINE NUCLEOTIDE ANALOGS AS FLUORESCENT DNA PROBES | THE GOVERNMENT OF THE UNITED STATES OF AMERICA, REPRESENTED BY THE SECRETARY OF THE DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 1995-11-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200131209-A1 | NOVEL STING AGONISTS | STING1, CGAS, TBK1 | NUDT1 1877/4885HRH4 365/4885MPO 3401/4885 |
| US-11161864-B2 | Sting agonists | STING1, IRF3, CGAS | NUDT1 2027/4885HRH4 447/4885MPO 3447/4885 |
| US-20220048936-A1 | NOVEL STING AGONISTS | STING1, IRF3, CGAS | NUDT1 1904/4885HRH4 380/4885MPO 3551/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.